Details
Stereochemistry | ACHIRAL |
Molecular Formula | C4H8O3 |
Molecular Weight | 104.1045 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OCCCC(O)=O
InChI
InChIKey=SJZRECIVHVDYJC-UHFFFAOYSA-N
InChI=1S/C4H8O3/c5-3-1-2-4(6)7/h5H,1-3H2,(H,6,7)
Molecular Formula | C4H8O3 |
Molecular Weight | 104.1045 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Sodium oxybate is the sodium salt of gamma-hydroxybutyrate (GHB), an endogenous metabolite of gamma-aminobutyric acid (GABA) a major inhibitory neurotransmitter. Evidence suggests a role for GHB as a neuromodulator/neurotransmitter. Under endogenous conditions and concentrations, and depending on the cell group affected, GHB may increase or decrease neuronal activity by inhibiting the release of neurotransmitters that are co-localised with GHB. After exogenous administration, most of the observed behavioural effects appear to be mediated via the activity of GHB at GABA(B) receptors, as long as the concentration is sufficient to elicit binding, which does not happen at endogenous concentrations. Xyrem (sodium oxybate) oral solution is indicated for the treatment of cataplexy in narcolepsy and excessive daytime sleepiness (EDS) in narcolepsy.
CNS Activity
Originator
Sources: Laborit H. (1964) Sodium 4-hydroxybutyrate. J Neuropharmacol 32: 433–452
Curator's Comment: Sodium oxybate (sodium salt of gamma-hydroxybutyrate (GHB) was first described as a possible precursor of GABA that could cross the blood-brain barrier [Laborit, 1964]. Further elucidation proved it an endogenous metabolite of GABA [Roth and Giarman, 1969] with a turnover of 0.16% of GABA being converted to GHB [Maitre, 1997] reference retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382678/
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2111463 Sources: http://pp.jazzpharma.com/pi/xyrem.en.USPI.pdf |
100.0 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | XYREM Approved UseXYREM® (sodium oxybate) oral solution is a central nervous system depressant indicated for the treatment of:
• Cataplexy in narcolepsy
• Excessive daytime sleepiness (EDS) in narcolepsy Launch Date1.02677761E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
54 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1389947 |
25 mg/kg 2 times / day multiple, oral dose: 25 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
23 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
25 mg/kg single, oral dose: 25 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
20 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
50 mg/kg single, oral dose: 50 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
23 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
12.5 mg/kg single, oral dose: 12.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3122 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1389947 |
25 mg/kg 2 times / day multiple, oral dose: 25 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
1271 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
25 mg/kg single, oral dose: 25 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1565 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
50 mg/kg single, oral dose: 50 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
905 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
12.5 mg/kg single, oral dose: 12.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
27 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1389947 |
25 mg/kg 2 times / day multiple, oral dose: 25 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
22 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
25 mg/kg single, oral dose: 25 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
23 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
50 mg/kg single, oral dose: 50 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
20 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
12.5 mg/kg single, oral dose: 12.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
99% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
12.5 mg/kg single, oral dose: 12.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 29, 35 |
no [IC50 >300 uM] | |||
Page: 29, 35 |
no [IC50 >300 uM] | |||
Page: 29, 35 |
no [IC50 >300 uM] | |||
Page: 29, 35 |
no [IC50 >300 uM] | |||
Page: 29, 35 |
no [IC50 >300 uM] | |||
Page: 29, 35 |
no [IC50 >300 uM] |
PubMed
Title | Date | PubMed |
---|---|---|
Circuit party attendance, club drug use, and unsafe sex in gay men. | 2001 |
|
The effect of gamma hydroxybutyrate on serum osmolality. | 2001 |
|
Long-term therapy using GHB (sodium gamma hydroxybutyrate) for treatment-resistant chronic alcoholics. | 2001 Apr-Jun |
|
Procedure of bidirectional selective outbreeding for production of two rat lines differing in sensitivity to the sedative/hypnotic effect of gamma-hydroxybutyric acid. | 2001 Aug |
|
Gamma-hydroxybutyrate, gamma-butyrolactone, and 1,4-butanediol. | 2001 Aug |
|
[Gamma hydroxy butyrate intoxication]. | 2001 Dec |
|
A comprehensive review of MDMA and GHB: two common club drugs. | 2001 Dec |
|
Drug use and sexual risk behavior among gay and bisexual men who attend circuit parties: a venue-based comparison. | 2001 Dec 1 |
|
GHB and driving impairment. | 2001 Jul |
|
Drug-facilitated date rape. | 2001 Jul 10 |
|
Multivariate curve resolution of wavelet and Fourier compressed spectra. | 2001 Jul 15 |
|
Baclofen antagonises intravenous self-administration of gamma-hydroxybutyric acid in mice. | 2001 Jul 20 |
|
[Effect of lithium hydroxybutyrate on the circadian dynamics of the urinary excretion of Li(+), Na(+), K(+), and Ca(2+) in rats depending on the circadian phase of the drug administration]. | 2001 Jul-Aug |
|
Characterization of partially transesterified poly(beta-hydroxyalkanoate)s by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. | 2001 Jul-Aug |
|
Response to the presence of gamma-hydroxybutyric acid (GHB) in postmortem biological fluids. | 2001 Jul-Aug |
|
Patient information. Date rape drugs: what parents should know. | 2001 Jun |
|
It's a rave new world: rave culture and illicit drug use in the young. | 2001 Jun |
|
The Circuit Party Men's Health Survey: findings and implications for gay and bisexual men. | 2001 Jun |
|
Metabolic flux in cellulose batch and cellulose-fed continuous cultures of Clostridium cellulolyticum in response to acidic environment. | 2001 Jun |
|
Dopaminergic changes in human brain following acute exposure to gamma-hydroxybutyrate. | 2001 Jun 12 |
|
[Biochemical parameters predictive of neuronal damage in childhood]. | 2001 Jun 16-30 |
|
Identification and effects of interaction phytotoxic compounds from exudate of Cistus ladanifer leaves. | 2001 Mar |
|
[Acute involuntary intoxication with gamma-hydroxybutyric acid]. | 2001 May |
|
[Gamma-hydroxybutyric acid-ethanolamide (LK 544). The suitability of LK 544 for sedation of patients in intensive care in comparison with midazolam]. | 2001 May |
|
Lack of efficacy of benzodiazepines in treating gamma-hydroxybutyrate withdrawal. | 2001 May |
|
GHB: an important pharmacologic and clinical update. | 2001 May-Aug |
|
Inheritance pattern of RAPD markers in Melipona quadrifasciata (Hymenoptera: Apidae, Meliponinae). | 2001 May-Jun |
|
Traumatic brain injury after a motor vehicle accident: fact or "fantasy"? | 2001 Nov |
|
Effects of endogenous neurotransmitters on the in vivo binding of dopamine and 5-HT radiotracers in mice. | 2001 Nov |
|
Management of gamma-hydroxybutyrate withdrawal. | 2001 Nov |
|
Window of detection of gamma-hydroxybutyrate in blood and saliva. | 2001 Nov |
|
The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. | 2001 Nov 15 |
|
Characteristics of pregnant women who use ecstasy (3, 4-methylenedioxymethamphetamine). | 2001 Nov-Dec |
|
[Autotrophic synthesis of polyalkanoates by Alcaligenes eutrophus in presence of carbon monoxide]. | 2001 Nov-Dec |
|
A contemporaneous finding of fenproporex in a polydrug suicide. | 2001 Oct |
|
Application of a convenient extraction procedure to analyze gamma-hydroxybutyric acid in fatalities involving gamma-hydroxybutyric acid, gamma-butyrolactone, and 1,4-butanediol. | 2001 Oct |
|
Pharmacologic rescue of lethal seizures in mice deficient in succinate semialdehyde dehydrogenase. | 2001 Oct |
|
Role of GABA(B) receptors in the sedative/hypnotic effect of gamma-hydroxybutyric acid. | 2001 Oct 12 |
|
GC-MS determination of gamma-hydroxybutyric acid (GHB) in blood. | 2001 Oct 15 |
|
Elevation of AKR7A2 (succinic semialdehyde reductase) in neurodegenerative disease. | 2001 Oct 19 |
|
[Well-documented information on GHB]. | 2001 Oct 3 |
|
Drugs, drink'n and smok'n. Part II. | 2001 Sep |
|
Discrimination of gamma-hydroxybutyrate and ethanol administered separately and as a mixture in rats. | 2001 Sep |
|
GHB. Club drug or confusing artifact? | 2001 Sep |
|
Use of physostigmine in the management of gamma-hydroxybutyrate overdose. | 2001 Sep |
|
Two cases of withdrawal from 1,4-Butanediol use. | 2001 Sep |
|
[GHB--dangerous, addictive and uncontrollable "party drug"]. | 2001 Sep 19 |
|
Prolonged withdrawal from extreme gamma-hydroxybutyrate (GHB) abuse. | 2001 Sep-Oct |
|
Using the overlapping parts of laboratory test panels to evaluate abnormal results. | 2001 Summer |
|
Comonomer unit composition and thermal properties of poly(3-hydroxybutyrate-co-4-hydroxybutyrate)s biosynthesized by Ralstonia eutropha. | 2001 Winter |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://pp.jazzpharma.com/pi/xyrem.en.USPI.pdf
Initiate dose at 4.5 grams (g) per night administered orally in two equal, divided doses: 2.25 g at bedtime and 2.25 g taken 2.5 to 4 hours later.
Titrate to effect in increments of 1.5 g per night at weekly intervals (0.75 g at bedtime and 0.75 g taken 2.5 to 4 hours later).
Recommended dose range: 6 g to 9 g per night orally.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11313294
Curator's Comment: gamma-hydroxybutyrate (GHB) activates both pre- and postsynaptic GABA(B)-receptors in neocortical neurons participating in fast synaptic transmission, leading to a powerful depression of neocortical network activity.
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 22:40:20 UTC 2023
by
admin
on
Wed Jul 05 22:40:20 UTC 2023
|
Record UNII |
30IW36W5B2
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EPA PESTICIDE CODE |
621757
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
||
|
NCI_THESAURUS |
C687
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
||
|
FDA ORPHAN DRUG |
5384
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
||
|
FDA ORPHAN DRUG |
694619
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
||
|
LIVERTOX |
NBK548588
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
||
|
LOINC |
59209-7
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
||
|
LOINC |
28041-2
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
||
|
LOINC |
28065-1
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
||
|
FDA ORPHAN DRUG |
26387
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
||
|
LOINC |
28038-8
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
||
|
FDA ORPHAN DRUG |
85894
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
||
|
LOINC |
29868-7
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
||
|
LOINC |
74920-0
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
||
|
NDF-RT |
N0000175758
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
||
|
LOINC |
47542-6
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
||
|
LOINC |
43198-1
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
||
|
DEA NO. |
2010
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
||
|
LOINC |
50148-6
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
||
|
LOINC |
72433-6
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
||
|
LOINC |
43197-3
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
||
|
LOINC |
44358-0
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
||
|
NDF-RT |
N0000175728
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
||
|
LOINC |
46085-7
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
||
|
NDF-RT |
N0000008501
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
||
|
LOINC |
68441-5
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
||
|
LOINC |
57746-0
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
||
|
LOINC |
68970-3
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
||
|
LOINC |
28044-6
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
||
|
LOINC |
68440-7
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
||
|
LOINC |
43194-0
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
10413
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
PRIMARY | |||
|
SUB32656
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
PRIMARY | |||
|
DTXSID2074740
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
PRIMARY | |||
|
16724
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
PRIMARY | |||
|
2387302
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
PRIMARY | |||
|
100000125890
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
PRIMARY | |||
|
GAMMA-HYDROXYBUTYRIC ACID
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
PRIMARY | |||
|
30830
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
PRIMARY | |||
|
30IW36W5B2
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
PRIMARY | |||
|
30IW36W5B2
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
PRIMARY | |||
|
C111420
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
PRIMARY | |||
|
4711
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
PRIMARY | |||
|
6927
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
PRIMARY | |||
|
591-81-1
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
PRIMARY | |||
|
M6124
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
PRIMARY | Merck Index | ||
|
DB01440
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
PRIMARY | |||
|
C61773
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
PRIMARY | |||
|
1546380
Created by
admin on Wed Jul 05 22:40:20 UTC 2023 , Edited by admin on Wed Jul 05 22:40:20 UTC 2023
|
ALTERNATIVE | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> AGONIST |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
PRECURSOR->PARENT |
GBL is typically marketed for sale as a cleaning solvent or polish. GBL is used as a GHB substitute and as a precursor for clandestine manufacturing of GHB.
|
||
|
SALT/SOLVATE -> PARENT | |||
|
LABELED -> NON-LABELED | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE | |||
|
METABOLITE -> PARENT |
succinic semialdehyde dehydrogenase converts succinic semialdehyde to succinic acid
|
||
|
METABOLITE -> PARENT |
nitiated by the action of GHB dehydrogenase
|
||
|
PARENT -> METABOLITE ACTIVE |
GBL is readily converted into GHB by the body’s own natural process. Because of this, GBL has similarpharmacological effects to GHB.
|
||
|
PARENT -> METABOLITE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |